Beijing Kangchuanglian Biopharmaceutical Technology Research

The clopidogrel aspirin tablets provided by Beijing Kangchuanglian Biopharmaceutical Technology Research Co., Ltd. were used as the test preparation, and the clopidogrel aspirin tablets (trade name: ComPlavin) produced by Sanofi Co., Ltd. were used as the reference preparation. According to the relevant regulations of bioequivalence studies, the bioequivalence of the test preparation and the reference preparation in healthy subjects under fasting and postprandial conditions was evaluated. The safety of healthy subjects after taking the test preparation clopidogrel aspirin tablets or the reference preparation clopidogrel aspirin tablets (trade name: ComPlavin) was observed.

Primary objective: To evaluate the effect of HD1916 on body weight in obese subjects compared with semaglutide injection. Secondary objective: To evaluate the effect of HD1916 on other clinical efficacy endpoints in obese subjects compared with semaglutide injection; Safety and immunogenicity of HD1916 in the treatment of obese subjects.

Indagamol Inhalation Powder (II) (Specification: 150 μg /50 μg/160 μg) developed by Beijing Kangchuanglian Biopharmaceutical Technology Research Co., Ltd. was used as the test preparation. According to the relevant provisions of the bioequivalence test, Indagamol Inhalation Powder (II) (Specification: 150 μg /50 μg/160 μg; Trade Name: Enerzair®) certified by Novartis Pharma AG was used as the reference preparation. The absorption rate and degree of absorption in healthy humans were compared to investigate the bioequivalence of the two preparations in humans. Secondary objective: To observe the safety of the test preparation Indagamol Inhalation Powder (II) and the reference preparation Indagamol Inhalation Powder (II) (Enerzair®) in healthy subjects.